Compare WAFD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | NUVB |
|---|---|---|
| Founded | 1917 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | WAFD | NUVB |
|---|---|---|
| Price | $33.31 | $8.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $31.40 | $10.63 |
| AVG Volume (30 Days) | 834.0K | ★ 10.3M |
| Earning Date | 01-15-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 5.31 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $717,732,000.00 | $26,748,000.00 |
| Revenue This Year | $8.66 | $609.55 |
| Revenue Next Year | $4.77 | $197.91 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | 1.95 | ★ 1137.19 |
| 52 Week Low | $23.75 | $1.54 |
| 52 Week High | $36.41 | $8.95 |
| Indicator | WAFD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 68.68 |
| Support Level | $32.70 | $7.80 |
| Resistance Level | $33.65 | $8.95 |
| Average True Range (ATR) | 0.68 | 0.50 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 79.82 | 70.76 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.